SynthesisThe Laryngoscope2026
GERD and Upper Aerodigestive Tract Cancer Risk: A Systematic Review and Meta-Analysis.
Synthesis in The Laryngoscope, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- In Response to GERD and Upper Aerodigestive Tract Cancer Risk: A Systematic Review and Meta-Analysis.The Laryngoscope · 2026Article
- In Reference to GERD and Upper Aerodigestive Tract Cancer Risk: A Systematic Review and Meta-Analysis.The Laryngoscope · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveGastroesophageal reflux disease (GERD) is highly prevalent, yet its association with upper aerodigestive tract (UADT) cancers beyond esophageal adenocarcinoma remains incompletely defined. This systematic review and meta-analysis aimed to quantify the risk of specific UADT cancers in individuals with GERD. DATA SOURCES: A comprehensive search of PubMed, Embase, Scopus, the Cochrane Library, and CINAHL was conducted for studies published from January 2000 to October 2024. REVIEW
methodsObservational studies (cohort or case-control) evaluating GERD as a risk factor for UADT cancers in adults were included, following PRISMA guidelines (PROSPERO: CRD42024602545). Esophageal adenocarcinoma was excluded due to its well-established association with GERD. Study quality was assessed using the Newcastle-Ottawa scale. Pooled relative risks (RR) and 95% confidence intervals (CI) were calculated using random effects models.
resultsSeventeen studies (12 case-control, 5 cohort), encompassing 1,768,394 participants, met inclusion criteria. GERD was significantly associated with laryngeal cancer (RR = 1.65, 95% CI = 1.19-2.31). No significant associations were found for pharyngeal, oropharyngeal, hypopharyngeal, or esophageal squamous cell carcinoma. Subgroup analysis showed stronger associations in U.S.-based studies (RR = 1.61) and in studies using ICD-coded GERD (RR = 1.93).
conclusionGERD is associated with an increased risk of laryngeal cancer. Findings support further investigation into reflux-related carcinogenesis in the UADT, particularly in high-risk populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.